

## 4. STENOTROPHOMONAS MALTOPHILIA

MH agar, McFarland 0.5, incubation air 35°C ± 1°C, incubation time 18h ± 2 h.

QC strains: *Pseudomonas aeruginosa* ATCC 27853, *Escherichia coli* ATCC 35218 (ticarcillin-clavulanate).

### • STANDARD PANEL (all specimen types)

**MDRO setting:** resistance to cotrimoxazole.

PRIMARY TESTING	SUGGESTED REPORTING (NON MDRO SETTING)	SUGGESTED REPORTING (MDRO SETTING)
Cotrimoxazole <sup>1</sup> .	+	+

SUPPLEMENTAL TESTING	SUGGESTED REPORTING (NON MDRO SETTING)	SUGGESTED REPORTING (MDRO SETTING)
Ceftazidime.	+	+
Ticarcillin-clavulanate.		+
Levofloxacin <sup>2</sup> .	+	+
Colistin <sup>3</sup> .		+
Minocycline or tigecycline.		+
Ceftolozane-tazobactam <sup>4</sup> .		
Ceftazidime-avibactam <sup>4</sup> .		

1. Only agent for which EUCAST clinical breakpoint is available; ignore fine haze and growth within inhibition zone; report resistant if growth up to the disk and no inhibition zone.
2. No clinical breakpoints recommended for ciprofloxacin.
3. Colistin susceptibility result should be verified by broth microdilution method if considered for treatment.
4. Testing not recommended as ceftolozane-tazobactam (not commercially available in Belgium) and ceftazidime-avibactam are inactive against *Stenotrophomonas maltophilia*.